What Gilead Sciences (GILD) Said on Its Q3 Earnings Call
Gilead Sciences (GILD) raised its 2026 sales forecast to $30.7B-$31B, citing strong HIV sales growth and new product launches. TRODELVY sales rose 42% YoY to $506M, while Livdelzi sales increased 93% YoY to $203M. Cell therapy sales declined 18% YoY. The company expects BIKTARVY revenue to be impacted by Medicare pricing but anticipates overall HIV revenue growth in 2028.
How this was made
The 30-second read
Why it matters
Traders can update models using the raised 2026 sales forecast and the quantified Medicare-driven net impact on Biktarvy revenue in 2028, while also tracking oncology and cell-therapy catalysts mentioned on the call.
Market read
The article provides concrete forward guidance and a quantified payer-channel revenue impact for Gilead’s core HIV franchise, which can drive near-term positioning and longer-dated valuation adjustments.
What to watch
Inventory building guidance (smaller Q4 build) and the timing of anito-cel FDA decision (Dec. 23) could dominate near-term sentiment versus the longer-dated 2028 Biktarvy impact.
Background
The piece summarizes Gilead’s Q3 earnings call, including new HIV product launch details, updated financial guidance, and payer pricing updates for Biktarvy.
Ticker impact
Gilead raised 2026 base business sales guidance and quantified a Medicare-driven net $1.5B 2028 Biktarvy revenue impact on its Q3 call.
Likely choppy trading as investors weigh higher 2026 outlook against the disclosed multi-year Biktarvy revenue drag from Medicare pricing.
The article includes specific forward guidance ranges and a quantified payer-channel impact tied to Biktarvy, which directly informs valuation and segment mix.
Market effects
Biopharma HIV and payer-pricing narratives may reprice as Medicare maximum fair price mechanics are quantified for a major franchise.
US-focused payer channel details (Medicare, Medicaid, 340B) can influence sentiment toward US commercial and government reimbursement dynamics.
European approvals and pipeline timelines can support broader investor risk appetite for HIV oncology cross-platform franchises, but the quantified impact is US-centric.
Counterpoint
The disclosed Biktarvy Medicare drag is netted and framed within a broader expectation of total HIV revenue growth, so the market may overreact to the headline pressure.
Key entities
- companyGilead Sciences
Raised 2026 base business sales forecast and disclosed a quantified Medicare-driven net impact on Biktarvy revenue in 2028.
- productBiktarvy
Medicare maximum fair price set at $2,600 per 30-day supply; company expects about $1.5B net revenue impact in 2028.
- productTRODELVY
Sales growth and a European approval update for TRODELVY plus pembrolizumab in first-line PD-L1-positive metastatic triple-negative breast cancer.
- productLivdelzi
Sales growth and plans for global filings to add Phase III IDEAL data, with potential US label update in 2027.
- pipeline_programanito-cel
Gilead/Kite preparing for a Dec. 23 FDA decision for fourth-line or later relapsed or refractory multiple myeloma.
